Table 1.

Characteristics of Children with ALL in Syria.

Characteristic	Count	Percentage (CI 95%)	Characteristic	Count	Percentage (CI 95%)
Gender			ALL subtype
Male	123	60.9 (54–67.8)	B ALL	158	79.8 (73.8–85.4)
Female	79	39.1 (32.2–46)	T ALL	40	20.2 (14.6–26.2)
Age (years)			WBC when diagnosed (cells/L)
0–4	74	36.6 (29.7–43.1)	1.5×109 and less	5	2.5
5–9	98	48.5 (42.1–55.9)	(1.5–11.5) × 109	91	45.7
10–14	30	14.9 (9.9–20.3)	11.5 × 109 and above	103	51.8
Place of living			Hemoglobin levels when diagnosed (g/dl)
Damascus	15	7.7	11–16	24	12
Rif-Dimashq	36	18.5	11–7	106	53
Aleppo	11	5.6	7 and less	70	35
Homs	20	10.3
Hama	22	11.3
Deir ez-Zur	17	8.7
Ar Raqqah	11	5.6
Al Hasakah	24	12.3	Platelets count (cells/L)
Daraa	10	5.1
As Suwayda	8	4.1	More than 400 × 109	4	2
Quneitra	1	0.5	(150 to 400) × 109	21	10.6
Latakia	4	2.1	(150 to 50) × 109	63	31.8
Tartus	4	2.1	(50 to 20) × 109	60	30.3
Idlib	12	6.2	Less than 20 × 109	50	25.3
Mother education level*			CXR
Low	91	56.2	Mediastinal enlargement or lymphadenopathies	32	18.4
Medium	55	34	Negative	142	81.6
High	16	9.9
Father education level*			CD 10
Low	88	53	81% and more	104	58.1
Medium	51	30.7	21–80%	36	20.1
High	27	16.3	20% and less	39	21.8
Main presenting symptom:			FAB classification
Systemic symptoms	140	74.9	L1	93	58.9 (51.3–65.8)
Lymphadenopathy	20	10.7	L2	57	36.1 (28.5–44.3)
Hepato-splenomegaly	5	2.7	L3	8	5.1 (1.9–8.9)
Bruising	16	8.6
Accidental	6	3.2
Hepato-splenomegaly:			Prognostic risk
Positive	139	73.2	Standard	96	51.6 (44.6–58.6)
Negative	51	26.8	High	90	48.4 (41.4–55.4)
Lymphadenopathy			Duration of symptoms before evaluation (weeks)
Positive	165	82.9	0–2
Negative	34	17.1	2–4	51	25.9
			4+	62	31.5
				84	42.6
Family history
Positive	20	10.6 (6.3–15.9)
Negative	169	89.4 (84.1–93.7)

CI: Confidence interval.